What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020) | BMJ Open

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

For authors

About

Browse by collection
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

PDF +
Supplementary
Material

Oncology

Original research

What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Jenei K, Haslam A, Olivier T, et al

What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020)

BMJ Open 2022;12:e064458. doi: 10.1136/bmjopen-2022-064458